Britannia Life Sciences Inc. BLAB
CNSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 273.37% | -59.92% | -- | 65.91% | 7.42% |
| Total Depreciation and Amortization | 0.88% | 6.54% | -- | 4.55% | 5.61% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -1,789.94% | 87.05% | -- | -112.48% | -83.33% |
| Change in Net Operating Assets | 13.24% | -1,479.74% | -- | -98.51% | -346.46% |
| Cash from Operations | 53.77% | 85.82% | -- | -678.33% | -10,946.32% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 4,513.06% | -100.00% | -- | -5,184.13% | -186.83% |
| Cash from Investing | 4,513.06% | -100.00% | -- | -5,184.13% | -186.83% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 17.45% | 97.63% | -- | -28.94% | -41.23% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 486.11% | 90.26% | -- | -115.54% | 94.32% |
| Foreign Exchange rate Adjustments | 372.09% | 112.24% | -- | -89.79% | -145.74% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 713.78% | -107.51% | -- | -2,440.59% | -191.77% |